Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   6/05/2024
109,85 USD (-0,15%)
(-0,15%)   6/05/2024

1 mei 2024 · Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference · Persbericht

1 mei 2024 · Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance · Persbericht

24 april 2024 · Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 · Persbericht

17 april 2024 · Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 · Persbericht

10 april 2024 · Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting · Persbericht

2 april 2024 · Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer · Persbericht

12 maart 2024 · Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 · Persbericht

28 februari 2024 · Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance · Persbericht

27 februari 2024 · Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors · Persbericht

21 februari 2024 · Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer · Persbericht

20 februari 2024 · Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences · Persbericht

14 februari 2024 · Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024 · Persbericht

7 februari 2024 · Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program · Persbericht

21 december 2023 · Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder · Persbericht

20 december 2023 · Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

8 december 2023 · Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer · Persbericht

1 december 2023 · Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting · Persbericht

8 november 2023 · Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance · Persbericht

7 november 2023 · Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers · Persbericht

1 november 2023 · Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences · Persbericht

Mijn selecties